Lifeboat Foundation

In what researchers have called an “unprecedented” response, a new drug that treats locally advanced rectal cancer has shown to have completely eradicated tumors in all 42 patients who took part in the Phase II trial.

The drug, Jemperli (dostarlimab-gxly), had earlier shown great potential for eliminating mismatch repair deficient (dMMR) cancers, which make up 5–10% of colorectal cancers. Following the Phase II trial, the first 24 patients assessed showed a “sustained complete clinical response” – no cancer evident – after an average of 26.3 months.

“These findings demonstrate the potential of dostarlimab-gxly as a novel approach to treating locally advanced dMMR rectal cancer that leads to durable complete tumor regression without the need for life-altering treatment,” said Dr Andrea Cercek, researcher and oncologist at the Memorial Sloan Kettering Cancer Center (MSK). “As a clinician, I’ve seen firsthand the debilitating impact of standard treatment of dMMR rectal cancer and am thrilled about the potential of dostarlimab-gxly in these patients.”

Basically confirmed whats been said here. AI will take over film making by 2029/2030.

Actor and entrepreneur Ashton Kutcher lauded OpenAI’s generative AI video tool Sora at a recent event. “I’ve been playing around with Sora, this latest thing that OpenAI launched that generates video,” Kutcher said. “I have a beta version of it, and it’s pretty amazing. Like, it’s pretty good.”

Continue reading “Actor and investor Ashton Kutcher Lauds OpenAI’s Video Model Sora” »

Prominent investor Ron Baron has come out in support of Tesla CEO Elon Musk’s $56 billion pay package, which is up for a shareholder vote next week, according to an open letter from the Baron Capital founder on Tuesday.

New long-term agreement will help provide responsive access to space for future tech demonstration spacecraft

Cedar Park, Texas, June 5, 2024 – Firefly Aerospace, Inc., an end-to-end space transportation company, today announced it signed a multi-launch agreement with Lockheed Martin for 25 launches on Firefly’s Alpha rocket through 2029. This agreement commits Lockheed Martin to 15 launch reservations and 10 optional launches.

“Firefly is honored to continue this partnership with Lockheed Martin and appreciates their confidence in our rapid launch services to support their critical missions for years to come,” said Bill Weber, CEO of Firefly Aerospace. “The Firefly team has scaled up Alpha production and testing and significantly streamlined our launch operations to fly Alpha more frequently and responsively. This allows us to continue delivering the one metric ton rocket the industry is demanding.”

SpaceX is targeting a launch at 8 a.m. EDT on June 6.

Making Humanity A Multi-Planetary Species — Dr. Eliah Overbey, Ph.D. — Assistant Professor, Bioastronautics, University of Austin; CSO, BioAstra.

Dr. Eliah Overbey, Ph.D. is Assistant Professor of Bioastronautics at The University of Austin (UATX — https://www.uaustin.org/people/eliah–…) where she is involved in pioneering research in the field of astronaut health, specializing in spaceflight-induced genomic changes. Her work focuses on mapping changes in the human body during spaceflight and developing Earth-independent laboratories to make humans a multi-planetary species (https://www.eliahoverbey.com/).

Continue reading “Dr. Eliah Overbey, Ph.D. — Assistant Prof., Bioastronautics, UATX — Making Humanity Multi-Planetary” »

The core theory, weak vs. strong emergence, micro-reductionism, and Sean Carroll’s skeptical argument against everything. Is Dr. Carroll correct in holding that physics has ruled out the afterlife, an immaterial soul, fundamental consciousness, and parapsychology?

Linktree https://linktr.ee/emersongreen.

Continue reading “Strong Emergence vs. The Core Theory (Response to Sean Carroll)” »

GCC19CART has previously been evaluated in an investigator-initiated clinical trial (ChiCTR2000040645) in China for the treatment of relapsed/refractory metastatic colorectal cancer (r/r mCRC).² Data from that trial showing improvements over standard of care (SOC) third-line therapies were presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14–19, 2023, in Orlando, Florida. Among the 21 patients included in the efficacy analysis, superior results were observed in patients (n=8) who received the higher dose level (2×10⁶ CAR-T cells/kg; DL2) than in patients (n=13) who received the lower dose level (1×10⁶ CAR-T cells/kg; DL1). The objective response rate was 50% (n=4) for DL2, 15% (n=2) for DL1, and 29% (n=6) for all patients.

“The new AE specific to this product is diarrhea because the target is guanylate cyclase 2C (GCC), which plays a role in intestinal homeostasis… So, that’s expected, theoretically,” Victor Lu, PhD, the chief technology officer of Innovative Cellular Therapeutics, who presented the data, said during his presentation.2 “Most patients treated with this product experienced diarrhea, but it can be controlled and because of the diarrhea management most of the patients actually recovered very quickly.”

GCC19CART targets both GCC and CD19.¹ It was designed using ICT’s CoupledCAR platform, which combines 2 CAR T cells engineered to release cytokines that are thought to promote proliferation and infiltration.³ The platform was designed following observations that CD19-directed CAR T cells also stimulated the immune system, which could lead to increase proliferation for other CAR T cells, specifically those directed toward solid tumor antigens, like GCC.

Subscribe: Newsletters: https://www.pbs.org/newshour/subscribePBS NewsHour podcasts: https://www.pbs.org/newshour/podcastsStream your PBS favorites with the P…